Biotechnology

Wednesday May 03, 2023 - 12:16 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Retains Analytics Firm, Investigates Possible Naked Short Selling

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is investigating potential naked short selling of its stock. As part of that process, the company has retained Shareholder Intelligence Services LLC (ShareIntel), a well-known analytics firm. ShareIntel will be evaluating trading patterns of CNSP stock as part of…

Monday May 01, 2023 - 9:35 am

InvestorNewsBreaks – Artella Solutions Inc. Names New Leadership Team Members, Announces Six-State Expansion

Artella Solutions, a company committed to advancing the well-being of patients with rhythm disorders while providing high-quality, real-time data to physicians for immediate viewing, announced that several industry veterans have joined the company’s national sales team as the Texas-based organization expands into six new markets: Arizona, Florida, Ohio, Michigan, New York and Pennsylvania. The strategic expansion is based on Artella’s best opportunities to capture market…

Tuesday Apr 25, 2023 - 10:15 am

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Closes on $1.9M Registered Direct Offering

Aditxt (NASDAQ: ADTX), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, announced that it has closed on its previously announced registered direct offering. The company transacted the closing with a single healthcare-focused institutional investor; the closing consisted of the purchase and sale of 1,585,350 shares of common stock (or common stock equivalents in lieu thereof), which were made…

Friday Apr 21, 2023 - 1:48 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advancing Potentially Pivotal Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP) recently reported the enrollment of the first patient in Switzerland as a participant in its ongoing potentially pivotal global trial evaluating Berubicin for the treatment of glioblastoma multiforme (“GBM”). “CNS Pharmaceutical’s adaptive, multicenter, open-label, randomized controlled study targets adult patients with recurrent GBM after failure of standard first-line therapy. In addition, the study will also enroll patients who have received additional…

Thursday Apr 20, 2023 - 9:50 am

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Inks Asset Purchase Agreement for 50% Ownership of Global Response Aid

Aditxt (NASDAQ: ADTX), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, has signed an asset purchase agreement with Cellvera Ltd. According to the announcement, the agreement gives Aditxt a 50% ownership in G Response Aid FZE; the remaining 50% ownership belongs to global logistics leader Agility Inc. Calling the agreement a “significant step” for the company, Aditxt officials…

Wednesday Apr 19, 2023 - 11:12 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in Equity Research Report

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, was featured in an equity research report published by Aegis Capital Corp. In the report, Aegis Capital maintained a buy rating for BVXV at a $70 target price. The publication reads, “R&D expenses for 2022 of $5.8 million were in-line with…

Tuesday Apr 18, 2023 - 9:51 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Reports FY 2022 Financial Statements, Corporate Update

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, published its full-year financial results for the year ended December 31, 2022; the report also included key business updates. Highlights of the report include the signing of definitive agreements with the Max Planck Society (“MPG”) and the University Medical Center…

Monday Apr 17, 2023 - 1:09 pm

InvestorNewsBreaks – Progressive Care Inc. (RXMD) Identified as a High-Growth Opportunity

Progressive Care (OTCQB: RXMD) offers services and technology that supports the managed health care industry to reduce costs and improve the quality of care. “The company has been steadily building both its pharmacy and data-management divisions as revenues continue to improve. However, a couple of extremely revealing events recently transpired that may have set the course for considerable upside potential. “The first inkling of something…

Monday Apr 17, 2023 - 10:28 am

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Releases Shareholder Update on Major Programs, M&A Plans

Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has released a shareholder update outlining its three innovation programs and strategic M&A initiatives. The update notes that subsidiary Pearsanta submitted a bid to acquire substantially all assets of Lucira Health Inc., including Lucira Connect and FDA-approved at-home combination COVID-19 and flu tests. The company was…

Friday Apr 14, 2023 - 11:30 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leveraging Innovative NanoAb Pipeline to Disrupt High-Value Market Opportunities

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. “In many compelling ways, BiondVax punches well above its weight compared to biopharma companies of similar market cap: BiondVax gained extensive drug development expertise [through previous clinical trials evaluating the M-001 universal influenza vaccine candidate], which is expected to be…

Wednesday Apr 12, 2023 - 12:59 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Provides Update on Spin-Out Plan, Announces Shareholder Meeting

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, plans to complete its spin-out transaction outlined in a plan of arrangement. The plan called for shares of the yet-to-be-formed wholly owned subsidiary to be separated into an independent public company. According to…

Monday Apr 10, 2023 - 1:06 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enrolls Over 100 Patients in Potentially Pivotal Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that more than 100 patients have been enrolled in the company’s potentially pivotal study with its lead product candidate, Berubicin. “We have long promised a study with a robust sample size sufficient to effectively determine Berubicin’s therapeutic…

Thursday Apr 06, 2023 - 12:28 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Adds Italy to Growing Portfolio of Countries for Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP) today announced its receipt of approval from the Italian Medicines Agency (“AIFA”) Competent Authority and the A.O.U. Policlinico di Bari Ethics Committee for its ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. According to the update, the company plans to open its clinical sites in Italy…

Monday Apr 03, 2023 - 2:56 pm

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Lead NanoAb Candidate Holds Significant Advantages to Existing Therapies

BiondVax (NASDAQ: BVXV), which focuses on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, has shown, through an ongoing in vivo preclinical proof-of-concept study, that its lead NanoAb candidate for the treatment of COVID-19 exhibits clear competitive advantages over existing monoclonal antibodies (“mAbs”) and oral therapies. “According to statistically significant results released early January, BiondVax established that…

Friday Mar 31, 2023 - 3:31 pm

InvestorNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW), Jupiter Wellness Acquisition Corp. Schedule Special Meeting for Approval of Proposed Business Combination

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair, skin, and sexual wellness, is reporting that the U.S. Securities and Exchange Commission ("SEC") has declared effective its registration statement. Jupiter Wellness, the business combination sponsor, observed that the registration statement was regarding Chijet Motor Company Inc., a developer of next-generation electric vehicles, in connection with a previously announced proposed business combination with Jupiter Wellness…

Thursday Mar 30, 2023 - 2:28 pm

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Poised to Offer Timely Solution amid a ‘Smoldering Public Health Crisis’

HeartBeam (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector electrocardiogram for heart attack detection anytime, anywhere. “A recent study shows that risk factors for cardiovascular (‘CV’) disease are rising among young adults… ‘Yet medical treatment rates for CV risk factors are ‘surprisingly low among young adults,’ study investigator Rishi Wadhera, MD, with Beth Israel Deaconess Medical Center and…

Thursday Mar 30, 2023 - 12:10 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Strategic Board Appointment of Gerry David

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced the appointment of Gerry David to its advisory board. David is best known for his five-year tenure as CEO at zero-calorie fitness drink maker Celsius Holdings Inc., where he spearheaded a…

Monday Mar 27, 2023 - 2:36 pm

InvestorNewsBreaks – Titan Partners Group LLC Announces Appointment of Life-Sciences Expert Dr. David Sans

Titan Partners Group, a division of American Capital Partners LLC (“Titan Partners”), today announced that Dr. David Sans has joined the firm as head of healthcare. Dr. Sans will lead the team that covers companies in the biopharmaceuticals, diagnostics, medtech and specialty pharmaceuticals sectors. “We are excited to bring in David Sans to join Titan Partners and lead our healthcare practice as we continue to…

Monday Mar 27, 2023 - 10:50 am

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent for Treatment of Fibromyalgia

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has filed a provisional patent application titled “Methods and Compositions for Pain Management.” The methods and compositions described in the patent application can be used in ameliorating pain, including chronic pain such as fibromyalgia, which is a chronic condition that occurs in approximately 2%…

Friday Mar 24, 2023 - 12:20 pm

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) NanoAb Holds Potential to Combat New COVID-19 Variants

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. “BiondVax is seeing convincingly positive outcomes for preventing and arresting disease in COVID patients during an ongoing preclinical in vivo study, even as continually evolving variants are shutting down emergency-use authorization (‘EUA’)-approved avenues of treatment that may no longer be…

Friday Mar 24, 2023 - 12:02 pm

InvestorNewsBreaks – Why Progressive Care Inc. (RXMD) Is ‘One to Watch’

Progressive Care (OTCQB: RXMD) is an organization based in Florida that, through its wholly owned subsidiaries PharmcoRx Pharmacy and ClearMetrX, offers personalized care services and technology to support the managed health care industries. “Progressive Care offers a wide range of innovative solutions to address the dispensing, delivery, dosing and reimbursement of clinically intensive, high-cost drugs. Progressive Care currently operates four pharmacies in Florida, which generate…

Friday Mar 24, 2023 - 11:43 am

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Positioned as Frontrunner in Psychedelic Drugs Market

Silo Pharma (NASDAQ: SILO) is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. “Silo Pharma has distinguished itself amongst peers for its ground-breaking research into conditions such as post-traumatic stress disorder (‘PTSD’), fibromyalgia, Alzheimer’s disease, and other rare neurological disorders. The company has recently entered into a number of studies designed to develop innovative solutions for previously underserved conditions,” a recent…

Friday Mar 24, 2023 - 11:25 am

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Poised to Enable Expedited Care for Heart Attack Patients

HeartBeam (NASDAQ: BEAT) is developing the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. “By applying a suite of proprietary algorithms to simplify vector electrocardiography (‘VECG’), the HeartBeam platform will enable patients and their clinicians to determine quickly and easily if symptoms are due to a heart attack so care can be expedited if required. HeartBeam has two patented products in…

Wednesday Mar 22, 2023 - 11:22 am

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) to Attend Investor Summit

IGC Pharma (NYSE American: IGC) (aka India Globalization Capital Inc.) today announced that its Chief Executive Officer Ram Mukunda and Principle Financial Officer Claudia Grimaldi will attend the Investor Summit on Wednesday, March 29, 2023. According to the update, Mukunda and Grimaldi will deliver a virtual company presentation at 11:30 a.m. ET and be available for virtual one-on-one meetings throughout the day. Interested investors should…

Wednesday Mar 22, 2023 - 11:16 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Subsidiary Receives Official Approval to Move Forward with Phase 1 Clinical Trial

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, announced that its Australian entity, FSD Pharma Australia Pty Ltd., has been approved to move forward with a key phase 2 clinical trial. The approval comes from the Alfred Ethics Committee in Australia,…

Wednesday Mar 22, 2023 - 9:51 am

InvestorNewsBreaks – Coeptis Therapeutics Holdings Inc. (NASDAQ: COEP) Tech Spotlighted in Article in Peer-Reviewed Translational Medicine Journal

Coeptis Therapeutics (NASDAQ: COEP), a biopharmaceutical company developing innovative cell therapy platforms for cancer, was spotlighted in the peer-reviewed “Journal of Translational Medicine.” The company’s SNAP-CAR technology was recognized in an article that detailed advances in modulating chimeric antigen receptor (“CAR”)-T cell activity for improved safety, efficacy and flexibility. SNAP-CAR is a multiantigen chimeric antigen receptor T cell technology that can be adapted to different…

Thursday Mar 16, 2023 - 3:04 pm

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO to Present at BIO-Europe Spring

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that its CEO Amir Reichman will be presenting in-person at the 17th annual BIO-Europe Spring. The event is slated to take place from March 20–22, 2023, in Basel, Switzerland, and draw over 2,800 executives from biotech, pharma and finance…

Wednesday Mar 15, 2023 - 1:29 pm

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Positive Results from IND-Enabling Toxicology Study of SP-26

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has achieved positive results for its toxicology study of SP-26, its novel time-released, dosage-controlled formulation of ketamine. In collaboration with Experimur, a Frontage Laboratories company, Silo Pharma tested SP-26 in a toxicology and tolerability study in mini pigs using an ascending (descending) dosing regimen…

Wednesday Mar 15, 2023 - 10:14 am

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Expands EU DuoPack Agreement by Including Insulin as Eligible Drug

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle and weight reduction programs, has added insulin onto the list of drugs under the DuoPack Commercial License Agreement with its licensee, MySugarWatch DuoPack Limited (“MSWDL”). Last September, Nemaura and MSWDL announced a commercial agreement making NMRD’s non-invasive wearable skin patch sensors available as a MySugarWatch-branded…

Tuesday Mar 14, 2023 - 1:19 pm

InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Acquires LIVEMOR Assets

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, has acquired substantially all assets from LIVMOR, a digital health solutions company. Specifically, LIVMOR offers a patient-engaging remote monitoring system of critical physiological biomarkers. The acquisition allows HeartBeam to extend its reach with LIVEMOR’s FDA-cleared Halo+(TM) Atrial Fibrillation Detection System and…

Tuesday Mar 14, 2023 - 12:41 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Engages ShareIntel to Investigate Possible Naked Short Selling of Its Stock

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced that it has renewed the service agreement with ShareIntel-Shareholder Intelligence Services LLC (www.ShareIntel.com). Under the agreement, ShareIntel will assist in ongoing investigations related to suspected naked short selling of FSD Pharma’s…

Monday Mar 13, 2023 - 2:36 pm

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) On Track to Advance Innovative Products

HeartBeam (NASDAQ: BEAT) is a cardiac technology company dedicated to finding effective ways to detect heart attacks earlier than ever before. “The company has two patented products in development: HeartBeam AIMI(TM), software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack more accurately; and HeartBeam AIMIGo(TM), the first and only credit-card-sized 12-lead output ECG…

Friday Mar 10, 2023 - 1:19 pm

InvestorNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Bringing Hope for Alzheimer’s Treatment

India Globalization Capital (NYSE American: IGC) is developing a cannabis-based investigational drug that is being tested for the first time ever on humans in an FDA-approved study. This is groundbreaking work that established its commitment as a pioneer in the treatment of Alzheimer’s disease, given there are no currently FDA-approved drugs to treat Alzheimer’s patients. “The company is developing its proprietary treatment, IGC-AD1, hoping to…

Thursday Mar 09, 2023 - 11:23 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enrolls First Patient in Switzerland in Potentially Pivotal Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that the first patient in Switzerland has been enrolled in the company’s ongoing global trial. The potentially pivotal trial is focused on evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form…

Wednesday Mar 08, 2023 - 12:23 pm

InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Makes Changes in Senior Leadership Roles

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, has made key leadership changes. The company announced that HeartBeam president Robert Eno has been appointed executive vice president while current chief business officer Jon Hunt, PhD, will transition into the role of strategic advisor and consultant, effective March 15, 2023.…

Wednesday Mar 08, 2023 - 11:31 am

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Appoints Veteran of Media Industry as Chief Content, Engagement Officer

Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has announced a new chief content and engagement officer. Maureen Connolly, an award-winning content strategic and audience builder, will step into the position. According to the announcement, Connolly has 20-plus years of experience in the health, wellness, science and technology sectors. She has proven expertise in…

Wednesday Mar 08, 2023 - 10:27 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Participate at Oppenheimer 33rd Annual Health Care Conference

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced that its Chief Executive Officer Doug Drysdale will participate at the Oppenheimer 33rd Annual Health Care Conference taking place on March 13-15, 2023. Drysdale’s fireside chat will be webcast live on Tuesday, March 14, at 12:40 p.m. ET. Interested parties should visit https://ibn.fm/4Qlqa to register for and access…

Wednesday Mar 08, 2023 - 9:52 am

InvestorNewsBreaks – Unicycive Therapeutics Inc. (NASDAQ: UNCY) Announces up to $130M to Commercialize and Launch Investigational New Drug

Unicycive (NASDAQ: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, has announced its entry into a securities purchase agreement with certain health care-focused institutional investors that will provide up to $130 million in gross proceeds to Unicycive through a private placement. According to the announcement, the private placement includes initial upfront funding of $30 million. Vivo Capital is leading the funding…

Tuesday Mar 07, 2023 - 11:45 am

InvestorNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Announces Clinical Trial of Jellyfish Sting Prevention Sunscreen on Man-O-War

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair, skin, and sexual wellness, has launched a clinical trial designed to explore the effectiveness of an improved formulation of NoStingz jellyfish sting prevention sunscreen against man-o-war jellyfish. The trial, which will be led by Dr. Patric Rice and Dr. Eric Stroud, will be conducted by Angelshark Consulting; the trial will take place in the Florida…

Monday Mar 06, 2023 - 1:00 pm

InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Reports on Debt Settlement Agreements

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and post-traumatic stress disorder, has announced debt settlements. According to the announcement, the company announced settlements for debt owed to some arms-length creditors, service providers and debtors of the company. The company noted that…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions